



Retinoblastoma—Current Therapeutic Challenges and Promising New Approaches

Guest Editors:

Prof. Dr. Nicole Dünker

Institute for Anatomy II,
Department of Neuroanatomy,
University of Duisburg-Essen,
University Medicine Essen, 45122
Essen, Germany

Prof. Dr. Norbert Bornfeld

Department of Ophthalmology,
University Hospital Essen, 45122
Essen, Germany

Prof. Dr. Francis L. Munier

Hôpital Ophtalmique Jules-
Gonin, University of Lausanne,
Switzerland

Deadline for manuscript
submissions:

closed (28 February 2021)

Message from the Guest Editors

Retinoblastoma (RB) is the most common primary intraocular tumor with an incidence of 1 in 14000 to 1 in 20000 per childbirths. Untreated, the tumor expands, may extend beyond the eye and develop metastatic spread. The advent of novel routes of chemotherapy administration, including intra-arterial, intravitreal and intracameral injections, has considerably improved the overall eye survival rate, eradicating the need for external beam radiotherapy, eliminating the risk of radio-induced malignancies, and reducing the indications for systemic chemotherapy. In this context, we welcome reviews and research articles summarizing the current state of the art in RB screening and treatment and future challenges as well as basic, preclinical and clinical studies. We are looking for studies on genes and miRNAs involved in the etiology and progression of RB, the potential impact of liquid biopsy and the development of chemoresistances. Other possible topics are promising new approaches including charged particle treatment, toxic chorioretinopathies, tumor invasion, metastasis and recurrence.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI